Henry Kao

5PUBLICATIONS
74CO-AUTHORS
Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

|Apr 07, 2026
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Elena Garralda, Christoph Markert, Victor Moreno

|Sep 17, 2025
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.

Irene Fusi, Clara Serger, Petra Herzig

|Dec 15, 2023
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.

Michael A Cannarile, Vaios Karanikas, Bernhard Reis

|Nov 01, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.

Marina Natoli, Klas Hatje, Pratiksha Gulati

Pageof 1

Frequent Collaborators

3 joint publications

Laura Codarri Deak

2 joint publications

Marina Natoli

2 joint publications

Klas Hatje

2 joint publications

Christian Klein